2. Stem Cell/Wnt MAPK/ERK Pathway NF-κB PI3K/Akt/mTOR Metabolic Enzyme/Protease Cell Cycle/DNA Damage Vitamin D Related/Nuclear Receptor Neuronal Signaling Immunology/Inflammation Apoptosis
  3. ERK p38 MAPK JNK NF-κB PI3K PPAR GSK-3 CaMK NO Synthase Reactive Oxygen Species Apoptosis
  4. Neoandrographolide

Neoandrographolide  (Synonyms: Neoandrographiside)

Cat. No.: HY-N0721 Purity: 99.65%
Data Sheet
SDS
COA
Handling Instructions Technical Support

Solubility

In Vivo Dissolution Calculator

Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity.

For research use only. We do not sell to patients.

Neoandrographolide Chemical Structure

Neoandrographolide Chemical Structure

CAS No. : 27215-14-1

Size Price Stock Quantity
10 mM * 1 mL in DMSO In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Neoandrographolide:

Top Publications Citing Use of Products

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All PPAR Isoform Specific Products:

View All Isoforms
PPARα PPARβ/δ PPARγ PPAR PPARδ

View All GSK-3 Isoform Specific Products:

View All Isoforms
GSK-3 GSK-3α GSK-3β

View All CaMK Isoform Specific Products:

View All Isoforms
CaMK II

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity[1][2][3][4][5].

Cellular Effect
Cell Line Type Value Description References
HL-60 GI50
26.67 μM
Compound: 5
Antiproliferative activity against human HL60 cells by trypan blue assay
Antiproliferative activity against human HL60 cells by trypan blue assay
[PMID: 18357994]
In Vitro

Neoandrographolide (0-30 μM, 6 days) inhibits osteoclast differentiation-related gene expression of NFATc1, c-Fos, CTSK and MMP9, inhibits RANKL-induced osteoclasts maturation in murine bone marrow macrophage[2].
Neoandrographolide (10-90 μM, 24 h) inhibits the expression of inflammatory factors TNF-α and IL-1β[3].
Neoandrographolide (7.5-150 μM, 24-36 h) inhibits PMA (HY-18739)-stimulated respiratory burst, inhibits LPS (HY-D1056)-induced TNF-α and NO production in cell RAW264.7[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR[2]

Cell Line: murine bone marrow macrophage
Concentration: 0-30 μM
Incubation Time: 6 days
Result: Inhibited the expression of NFATc1, c-Fos, CTSK and MMP9.
In Vivo

Neoandrographolide (15-30 mg/kg, ip, 3 times a week for 8 weeks) alleviates OVX-induced osteoporosis in mouse models[2].
Neoandrographolide (10 mg/kg, ip, once a day for 6 days) alleviates the ischemia-reperfusion injury in mouse models[3].
Neoandrographolide (50-150 mg/kg, po, single dose) inhibits Dimethyl benzene-induced ear edema, exhibits anti-inflammatory activity in mouse models[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: OVX-induced osteoporosis in mouse models[2]
Dosage: 15-30 mg/kg
Administration: ip, 3 times a week for 8 weeks
Result: Alleviated OVX-induced bone loss.
Animal Model: Mouse myocardial ischemia-reperfusion injury model[3]
Dosage: 10 mg/kg
Administration: ip, once a day for 6 days
Result: Improved the cardiac contractile function, reduced the levels of myocardial injury markers (CK-MB and cTNI), reduced infarction area.
Animal Model: Dimethyl benzene-induced ear edema in mouse models[4]
Dosage: 50-150 mg/kg
Administration: po, single dose
Result: Inhibited ear edema at a dose of 150 mg/kg.
Molecular Weight

480.59

Formula

C26H40O8
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

C[C@@]([C@@H]1CCC2=CCOC2=O)(CCC3)[C@@](CCC1=C)([H])[C@]3(C)CO[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (208.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0808 mL 10.4039 mL 20.8078 mL
5 mM 0.4162 mL 2.0808 mL 4.1616 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 25 mg/mL (52.02 mM); Clear solution

    This protocol yields a clear solution of ≥ 25 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (250.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.20 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, PEG300/PEG400, Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Purity & Documentation

Purity: 99.65%

Data Sheet (280 KB) SDS (393 KB)

COA (252 KB) HNMR (204 KB) LCMS (115 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.0808 mL 10.4039 mL 20.8078 mL 52.0194 mL
5 mM 0.4162 mL 2.0808 mL 4.1616 mL 10.4039 mL
10 mM 0.2081 mL 1.0404 mL 2.0808 mL 5.2019 mL
15 mM 0.1387 mL 0.6936 mL 1.3872 mL 3.4680 mL
20 mM 0.1040 mL 0.5202 mL 1.0404 mL 2.6010 mL
25 mM 0.0832 mL 0.4162 mL 0.8323 mL 2.0808 mL
30 mM 0.0694 mL 0.3468 mL 0.6936 mL 1.7340 mL
40 mM 0.0520 mL 0.2601 mL 0.5202 mL 1.3005 mL
50 mM 0.0416 mL 0.2081 mL 0.4162 mL 1.0404 mL
60 mM 0.0347 mL 0.1734 mL 0.3468 mL 0.8670 mL
80 mM 0.0260 mL 0.1300 mL 0.2601 mL 0.6502 mL
100 mM 0.0208 mL 0.1040 mL 0.2081 mL 0.5202 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Neoandrographolide Related Classifications

Keywords:

Neoandrographolide27215-14-1NeoandrographisideERKp38 MAPKJNKNF-κBPI3KPPARGSK-3CaMKNO SynthaseReactive Oxygen SpeciesApoptosisExtracellular signal regulated kinasesc-Jun N-terminal kinaseNuclear factor-κBNuclear factor-kappaBPhosphoinositide 3-kinasePeroxisome proliferator-activated receptorsGlycogen synthase kinase-3Glycogen synthase kinase 3Calmodulin-dependent protein kinasesCalmodulin-dependent kinasesNitric oxide synthasesNOSC57BL/6J mouseosteoporosisH9C2RAW 264.7BALB/c mouseInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Neoandrographolide
Cat. No.:
HY-N0721
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.